-
Mashup Score: 35Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers - 14 day(s) ago
The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation and ACLF. As portal hypertension advances, bacterial translocation across an impaired gut barrier culminates in endotoxaemia, systemic inflammation and cirrhosis-associated immune dysfunction (CAID). Gut-derived systemic inflammation and CAID have become the logical targets for innovative therapies that prevent hepatic decompensation episodes and the progression to ACLF. Furthermore, classification of disease and biomarker discovery to personalise care have advanced in the field. This review discusses progress in biomarker discovery and personalisation of treatment in decompensated
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 35Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers - 21 day(s) ago
The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation and ACLF. As portal hypertension advances, bacterial translocation across an impaired gut barrier culminates in endotoxaemia, systemic inflammation and cirrhosis-associated immune dysfunction (CAID). Gut-derived systemic inflammation and CAID have become the logical targets for innovative therapies that prevent hepatic decompensation episodes and the progression to ACLF. Furthermore, classification of disease and biomarker discovery to personalise care have advanced in the field. This review discusses progress in biomarker discovery and personalisation of treatment in decompensated
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
Read the #RecentAdvancesInClinicalPractice paper on "Recent advances in the prevention & treatment of decompensated cirrhosis & acute-on-chronic liver failure & the role of biomarkers" via https://t.co/BqwvAYBf63 @JonelTrebicka @ruben_hernaez @DebbieShawcros1 @AlexanderGerbes https://t.co/MEq074vo8B
-
-
Mashup Score: 35Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers - 28 day(s) ago
The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation and ACLF. As portal hypertension advances, bacterial translocation across an impaired gut barrier culminates in endotoxaemia, systemic inflammation and cirrhosis-associated immune dysfunction (CAID). Gut-derived systemic inflammation and CAID have become the logical targets for innovative therapies that prevent hepatic decompensation episodes and the progression to ACLF. Furthermore, classification of disease and biomarker discovery to personalise care have advanced in the field. This review discusses progress in biomarker discovery and personalisation of treatment in decompensated
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
Read the #RecentAdvancesInClinicalPractice paper on "Recent advances in the prevention & treatment of decompensated cirrhosis & acute-on-chronic liver failure & the role of biomarkers" via https://t.co/BqwvAYBf63 @JonelTrebicka @ruben_hernaez @DebbieShawcros1 @AlexanderGerbes https://t.co/MEq074vo8B
-
-
Mashup Score: 35Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers - 1 month(s) ago
The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation and ACLF. As portal hypertension advances, bacterial translocation across an impaired gut barrier culminates in endotoxaemia, systemic inflammation and cirrhosis-associated immune dysfunction (CAID). Gut-derived systemic inflammation and CAID have become the logical targets for innovative therapies that prevent hepatic decompensation episodes and the progression to ACLF. Furthermore, classification of disease and biomarker discovery to personalise care have advanced in the field. This review discusses progress in biomarker discovery and personalisation of treatment in decompensated
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
Read the #RecentAdvancesInClinicalPractice paper on "Recent advances in the prevention & treatment of decompensated cirrhosis & acute-on-chronic liver failure & the role of biomarkers" via https://t.co/BqwvAYBf63 @JonelTrebicka @ruben_hernaez @DebbieShawcros1 @AlexanderGerbes https://t.co/MEq074vo8B
-
-
Mashup Score: 34Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers - 1 month(s) ago
The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation and ACLF. As portal hypertension advances, bacterial translocation across an impaired gut barrier culminates in endotoxaemia, systemic inflammation and cirrhosis-associated immune dysfunction (CAID). Gut-derived systemic inflammation and CAID have become the logical targets for innovative therapies that prevent hepatic decompensation episodes and the progression to ACLF. Furthermore, classification of disease and biomarker discovery to personalise care have advanced in the field. This review discusses progress in biomarker discovery and personalisation of treatment in decompensated
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
Read the #RecentAdvancesInClinicalPractice paper on "Recent advances in the prevention & treatment of decompensated cirrhosis & acute-on-chronic liver failure & the role of biomarkers" via https://t.co/BqwvAYBf63 @JonelTrebicka @ruben_hernaez @DebbieShawcros1 @AlexanderGerbes https://t.co/MEq074vo8B
-
-
Mashup Score: 0Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease - 7 month(s) ago
Drug rediscovery refers to the principle of using ‘old’ drugs outside the indications mentioned in the summary of product characteristics. In the past decades, several drugs were rediscovered in a wide variety of medical fields. One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands. In this paper, we aim to visualise potential hurdles that hamper drug rediscovery in general, emphasise the global need for optimal use and development of potentially useful drugs, and provide an overview of the registration process for TG in the Netherlands. With this summary, we aim to guide drug rediscovery trajectories in the near future.
Source: gut.bmj.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 1Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease - 7 month(s) ago
Drug rediscovery refers to the principle of using ‘old’ drugs outside the indications mentioned in the summary of product characteristics. In the past decades, several drugs were rediscovered in a wide variety of medical fields. One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands. In this paper, we aim to visualise potential hurdles that hamper drug rediscovery in general, emphasise the global need for optimal use and development of potentially useful drugs, and provide an overview of the registration process for TG in the Netherlands. With this summary, we aim to guide drug rediscovery trajectories in the near future.
Source: gut.bmj.comCategories: Gastroenterology, Latest HeadlinesTweet
Read the #RecentAdvancesInClinicalPractice paper on "Recent advances in the prevention & treatment of decompensated cirrhosis & acute-on-chronic liver failure & the role of biomarkers" via https://t.co/BqwvAYBf63 @JonelTrebicka @ruben_hernaez @DebbieShawcros1 @AlexanderGerbes https://t.co/MEq074vo8B